Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, Raphael A., Towers, Terri L., Presta, Leonard G., Ravetch, Jeffrey V.·2000·Nature Medicine
DOI 10.1038/74704

Cited by (1,006)

Items 501–600 of 1,006

  1. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G
    Susanne Preithner, Stefanie Elm, Sandra Lippold, Mathias Locher, Andreas Wolf, Antonio J. da Silva, Patrick A. Baeuerle, Nadja S. Prang · 2005 · Molecular Immunology
  2. Epidermal Growth Factor Receptor as a Therapeutic Target in Colorectal Cancer
    Roger B. Cohen · 2003 · Clinical Colorectal Cancer
  3. Untitled work
    Imai-Nishiya · 2007 · 10.1186/1472-6750-7-84
  4. The future of anti-CD20 monoclonal antibodies: are we making progress?
    Waleed Alduaij, Tim Illidge · 2011 · Blood
  5. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
    Josée Golay, Elena Cittera, Nicola Di Gaetano, Massimiliano Manganini, Michela Mosca, Manuela Nebuloni, Nico van Rooijen, Luca Vago, Martino Introna · 2006 · PubMed
  6. Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
    Stéphane Dalle, Lina Reslan, Timothee Besseyre de Horts, Stéphanie Herveau, Frank Herting, Adriana Pleșa, Thomas Friess, Pablo Umaña, Christian Klein, Charles Dumontet · 2011 · Molecular Cancer Therapeutics
  7. HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
    Merel Gijsen, Peter King, Tim Perera, Peter J. Parker, Adrian Llewellyn Harris, Banafshé Larijani, Anthony H. Kong · 2010 · PLoS Biology
  8. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects
    Andrea L. Rose, Barbara E. Smith, David G. Maloney · 2002 · Blood
  9. Immune Response Against Dying Tumor Cells
    Laurence Zitvogel, Noëlia Casares, Marie O. Péquignot, Nathalie Chaput, Matthew L. Albert, Guido Kroemer · 2004 · Advances in immunology
  10. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival
    Issa F. Khouri, Ming-Sheng Lee, Rima M. Saliba, Börje S. Andersson, Paolo N. Anderlini, Daniel R. Couriel, Chitra M. Hosing, Sergio A. Giralt, Martin J. Korbling, John D. McMannis et al. · 2004 · Experimental Hematology
  11. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20
    David Daydé, David Ternant, Marc C. P. Ohresser, Stéphanie Lerondel, Sabrina Pesnel, Hervé Watier, Alain Le Pape, PIERRE BARDOS, Gilles Paintaud, Guillaume Cartron · 2008 · Blood
  12. Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cancer Stem Cells
    Florian Reim, Yvonne Dombrowski, Cathrin Ritter, Mathias Buttmann, Sebastian F. Häusler, Monika Ossadnik, Mathias Krockenberger, Dagmar Beier, Christoph Patrick Beier, J. Dietl et al. · 2009 · Cancer Research
  13. Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab
    Hee Jin Lee, Joo Young Kim, In Ah Park, In Hye Song, Jong Han Yu, Jin‐Hee Ahn, Gyungyub Gong · 2015 · American Journal of Clinical Pathology
  14. Complement in monoclonal antibody therapy of cancer
    Laura M. Rogers, Suresh Veeramani, George J. Weiner · 2014 · Immunologic Research
  15. In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling
    Simone de Haij, J.H. Marco Jansen, Péter Boross, Frank J M Beurskens, Jantine E. Bakema, Desirée L. Bos, Anton C. Martens, J. Sjef Verbeek, Paul W.H.I. Parren, Jan G. J. van de Winkel et al. · 2010 · Cancer Research
  16. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
    Per Soelberg Sørensen, Morten Blinkenberg · 2015 · Therapeutic Advances in Neurological Disorders
  17. Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy
    David J. Zahavi, Dalal S. Aldeghaither, Allison O’Connell, Louis M. Weiner · 2018 · Antibody Therapeutics
  18. Resistance and Overcoming Resistance in Breast Cancer
    Andrea Luque-Bolivar, Erika Pérez-Mora, Victoria Eugenia Villegas, Milena Rondón‐Lagos · 2020 · Breast Cancer Targets and Therapy
  19. The biology of natural killer cells in cancer, infection, and pregnancy
    Jeffrey S. Miller · 2001 · Experimental Hematology
  20. Dysregulation of cellular signaling by HER2 in breast cancer
    Binhua Peter Zhou · 2003 · Seminars in Oncology
  21. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
    Antonio Marra, Sarat Chandarlapaty, Shanu Modi · 2024 · Nature Reviews Clinical Oncology
  22. EphB2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Cancer
    Weiguang Mao, Elizabeth Luis, Sarajane Ross, Johnny Silva, Christine Tan, Craig W. Crowley, C.H. Chui, Gretchen Franz, Peter D. Senter, Hartmut Koeppen et al. · 2004 · Cancer Research
  23. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: A new strategy for generating completely non-fucosylated recombinant therapeutics
    Yutaka Kanda, Harue Imai, Reiko Kuni‐Kamochi, Katsuhiro Mori, Miho Inoue, Kazuko Kitajima-Miyama, Akira Okazaki, Shigeru Iida, Kenya Shitara, Mitsuo Satoh · 2007 · Journal of Biotechnology
  24. Antibody-Dependent Cell Cytotoxicity Synapses Form in Mice during Tumor-Specific Antibody Immunotherapy
    Pascale Hubert, Adèle Heitzmann, Sophie Viel, André Nicolas, Xavier Sastre‐Garau, Pablo Oppezzo, Otto Pritsch, Eduardo Osinaga, Sebastián Amigorena · 2011 · Cancer Research
  25. Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays
    Josée Golay, Martino Introna · 2012 · Archives of Biochemistry and Biophysics
  26. Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis
    Paul V. Beum, Margaret A. Lindorfer, Frank J M Beurskens, P. Todd Stukenberg, Henk M. Lokhorst, Andrew W. Pawluczkowycz, Paul W.H.I. Parren, Jan G. J. van de Winkel, Ronald P. Taylor · 2008 · The Journal of Immunology
  27. NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival
    Aura Muntasell, Federico Rojo, Sònia Servitja, Carlota Rubio-Pérez, Mariona Cabo, David Tamborero, Marcel Costa-García, Maria Martinez‐García, Sílvia Menéndez, Ivonne Vázquez et al. · 2019 · Clinical Cancer Research
  28. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience
    T Shaw, J Quan, M C Totoritis · 2003 · Annals of the Rheumatic Diseases
  29. Immunotherapy of cancer
    Hossein Borghaei, Mitchell Reed Smith, Kerry S. Campbell · 2009 · European Journal of Pharmacology
  30. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia
    Lapo Alinari, Rosa Lapalombella, Leslie Ann Andritsos, Robert A. Baiocchi, Thomas S. Lin, John C. Byrd · 2007 · Oncogene
  31. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model
    Asahi Ito, Takashi Ishida, Hiroki Yano, Atsushi Inagaki, Susumu Suzuki, Fumihiko Sato, Hisashi Takino, Fumiko Mori, Masaki Ri, Shigeru Kusumoto et al. · 2008 · Cancer Immunology Immunotherapy
  32. Use of Trastuzumab Beyond Disease Progression: Observations from a Retrospective Review of Case Histories
    Karen A. Gelmon, John Robert Mackey, Shailendra Verma, Stan Z. Gertler, Nikola Bangemann, Paul Klimo, Andreas Schneeweiß, Karl Bremer, Denis Soulières, Katia Sonia Tonkin et al. · 2004 · Clinical Breast Cancer
  33. Fcγ Receptors and Cross-Presentation in Dendritic Cells
    Sebastián Amigorena · 2002 · The Journal of Experimental Medicine
  34. Preclinical Antilymphoma Activity of a Humanized Anti-CD40 Monoclonal Antibody, SGN-40
    Che‐Leung Law, Kristine A. Gordon, John Collier, Kerry Klussman, Julie A. McEarchern, Charles G. Cerveny, Bruce J. Mixan, Wyne P. Lee, Zhonghau Lin, Patricia A Valdez et al. · 2005 · Cancer Research
  35. Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms
    Kirstie L.S. Cleary, H.T. Claude Chan, Sonja James, Martin J. Glennie, Mark Steven Cragg · 2017 · The Journal of Immunology
  36. Complement in therapy and disease
    Joost P.M. Melis, Kristin Strumane, Sigrid R. Ruuls, Frank J M Beurskens, Janine Schuurman, Paul W.H.I. Parren · 2015 · Molecular Immunology
  37. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.
    Koji Kono, Akihiro Takahashi, Fumiko Ichihara, Hidemitsu Sugai, Hideki Fujii, Yoshirou Matsumoto · 2002 · PubMed
  38. Rational therapeutic intervention in cancer: kinases as drug targets
    Charles L. Sawyers · 2002 · Current Opinion in Genetics & Development
  39. Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake
    Marlous Arjaans, Thijs H. Oude Munnink, Sjoukje F. Oosting, Anton G.T. Terwisscha van Scheltinga, Jourik A. Gietema, Erik T. Garbacik, Hetty Timmer‐Bosscha, Marjolijn N. Lub–de Hooge, Carolina Pia Schroder, Elisabeth G.E. de Vries · 2013 · Cancer Research
  40. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo –Expanded Autologous NK Cells
    Yufeng Wang, Yibo Zhang, Tiffany L. Hughes, Jianying Zhang, Michael A. Caligiuri, Don M. Benson, Jianhua Yu · 2018 · Clinical Cancer Research
  41. An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
    Andrew P. Garner, Carl Uli Bialucha, Elizabeth R. Sprague, Joan T. Garrett, Qing Sheng, Sharon Li, Olga Sineshchekova, Parmita Saxena, Cammie R. Sutton, Dongshu Chen et al. · 2013 · Cancer Research
  42. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
    Sarat Chandarlapaty, Maurizio Scaltriti, Pier Davide Angelini, Q Ye, Marta Guzmán, Clifford A. Hudis, Larry Norton, David B. Solit, Joaquı́n Arribas, Jose M Baselga et al. · 2009 · Oncogene
  43. Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses
    Xuanming Yang, Xunmin Zhang, Eric D. Mortenson, Olga Radkevich-Brown, Yang Wang, Yang‐Xin Fu · 2012 · Molecular Therapy
  44. A potent human neutralizing antibody Fc-dependently reduces established HBV infections
    Dan Li, Wenhui He, Ximing Liu, Sanduo Zheng, Yonghe Qi, Huiyu Li, Fengfeng Mao, Juan Liu, Yinyan Sun, Lijing Pan et al. · 2017 · eLife
  45. Monoclonal antibody mechanisms of action in cancer
    George J. Weiner · 2007 · Immunologic Research
  46. Immunotherapy for Renal Cell Carcinoma
    Ivar Bleumer, Egbert Oosterwijk, Pieter De Mulder, Peter Mulders · 2003 · European Urology
  47. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas
    Claudia Curcio, Emma Di Carlo, Raphael Clynes, Mark John Smyth, Katia Boggio, Elena Quaglino, Michela Spadaro, Mario P. Colombo, Augusto Roca De Amici, Pier‐Luigi Lollini et al. · 2003 · Journal of Clinical Investigation
  48. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells
    Michael Stanglmaier, Simone Reis, Michael J. Hallek · 2004 · Annals of Hematology
  49. Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
    Afshin Derakhshani, Zohreh Rezaei, Hossein Safarpour, Morteza Sabri, Atefeh Mir, Mohammad Amin Sanati, Fatemeh Vahidian, Ali Gholamiyan Moghadam, Ali Aghadoukht, Khalil Hajiasgharzadeh et al. · 2019 · Journal of Cellular Physiology
  50. Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
    Merel Gijsen, Peter King, Tim Perera, Peter J. Parker, Adrian Llewellyn Harris, Banafshé Larijani, Anthony H. Kong · 2016 · PLoS Biology
  51. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy
    Andrew Hiatt, Natasha Bohorova, Ognian Bohorov, Charles A. Goodman, Do Kim, Michael H. Pauly, Jesús Velasco, Kevin J. Whaley, Pedro A. Piedra, Brian E. Gilbert et al. · 2014 · Proceedings of the National Academy of Sciences
  52. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
    Andrew J.S. Furness, Frederick Arce Vargas, Karl S. Peggs, Sergio A. Quezada · 2014 · Trends in Immunology
  53. Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti–CTLA-4 antibodies
    Kenneth D. Lute, Kenneth F. May, Ping Lu, Huiming Zhang, Ergun Kocak, Bedrick Mosinger, Christopher C. Wolford, Gary S. Phillips, Michael A. Caligiuri, Pan Zheng et al. · 2005 · Blood
  54. Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients
    Frank J M Beurskens, Margaret A. Lindorfer, Mohammed Z. H. Farooqui, Paul V. Beum, Patrick J. Engelberts, Wendy J.M. Mackus, Paul W.H.I. Parren, Adrian U. Wiestner, Ronald P. Taylor · 2012 · The Journal of Immunology
  55. Influence of immunoglobulin isotype on therapeutic antibody function
    Stephen A. Beers, Martin J. Glennie, Ann L. White · 2016 · Blood
  56. Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo
    Darren J. Schofield, Lorraine M. Irving, Laura Calò, Anna Bogstedt, Gareth Rees, Annalisa Nuccitelli, Rajesh Narwal, Marcella Petrone, Jennifer Roberts, Lee Brown et al. · 2019 · Neurobiology of Disease
  57. Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets
    Julie M. Roda, Robin Parihar, Amy Lehman, Aruna Mani, Susheela Tridandapani, William Edgar Carson · 2006 · The Journal of Immunology
  58. GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab
    Christian A. Gerdes, Valeria Nicolini, Sylvia Herter, Erwin van Puijenbroek, Sabine Lang, Michaela Roemmele, Ekkehard Moessner, Olivier Freytag, Thomas Friess, Carola Hermine Ries et al. · 2012 · Clinical Cancer Research
  59. IgA EGFR antibodies mediate tumour killing in vivo
    Péter Boross, Stefan Lohse, Maaike Nederend, J.H. Marco Jansen, Geert van Tetering, Michael Dechant, Matthias Peipp, Louise Royle, Li Phing Liew, Louis Boon et al. · 2013 · EMBO Molecular Medicine
  60. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.
    Christian Meyer zum Büschenfelde, Christine Hermann, Burkhard Schmidt, Christian Peschel, Helga Bernhard · 2002 · PubMed
  61. CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis
    Li-Chung Tsao, Erika J. Crosby, Timothy N. Trotter, Pankaj Agarwal, Bin-Jin Hwang, Chaitanya R. Acharya, Casey W. Shuptrine, Tao Wang, Jun-Ping Wei, Xiao Yi Yang et al. · 2019 · JCI Insight
  62. Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond
    Celeste M. Bello, Eduardo M. Sotomayor · 2007 · Hematology
  63. A Novel Class of Small Molecule Inhibitors of Hsp90
    Fang Yi, Lynne Regan · 2008 · ACS Chemical Biology
  64. Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy
    Xu Cao, Jing Chen, Bolei Li, Jessica Dang, Wencan Zhang, Xiancai Zhong, Chongkai Wang, Mustafa Raoof, Zuoming Sun, Jianhua Yu et al. · 2022 · Science Advances
  65. Oncogenes and tumor suppressor genes: functions and roles in cancers
    Tikam Chand Dakal, Bhanupriya Dhabhai, Anuja Pant, Kareena Moar, Kanika Chaudhary, Vikas Yadav, Vipin Ranga, Narendra Kumar Sharma, Abhishek Kumar, Pawan Kumar Maurya et al. · 2024 · MedComm
  66. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
    Karim S. ElSahwi, Stefania Bellone, Emiliano Cocco, Marilisa Cargnelutti, Francesca Casagrande, Marta Bellone, MM Abu-Khalaf, Natália Buza, Fattaneh A. Tavassoli, Pei Hui et al. · 2009 · British Journal of Cancer
  67. Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format
    Lillian Shahied, Yong Tang, R. Katherine Alpaugh, Robert A. Somer, Dana Greenspon, Louis M. Weiner · 2004 · Journal of Biological Chemistry
  68. Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates
    Che‐Leung Law, Charles G. Cerveny, Kristine A. Gordon, Kerry Klussman, Bruce J. Mixan, Dana F. Chace, Damon L. Meyer, Svetlana O. Doronina, Clay B. Siegall, Joseph A. Francisco et al. · 2004 · Clinical Cancer Research
  69. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients
    Hurvitz, Sara A., Betting, David J., Stern, Howard M., Quinaux, Emmanuel, Stinson, Jeremy, Seshagiri, Somasekar, Zhao, Ying, Buyse, Marc, Mackey, John, Driga, Adrian et al. · 2012 · Clinical Cancer Research
  70. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
    Sari Riihijärvi, Idun Fiskvik, Mervi H. Taskinen, Heli Vajavaara, M. Tikkala, Olav Erich Yri, Marja‐Liisa Karjalainen‐Lindsberg, Jan Delabie, Erlend Bremertun Smeland, Harald Holte et al. · 2014 · Haematologica
  71. Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner
    Caitlin E. Mullarkey, Mark J. Bailey, Diana Golubeva, Gene S. Tan, Raffael Nachbagauer, Wenqian He, Kyle E. Novakowski, Dawn M. E. Bowdish, Matthew S. Miller, Peter Palese · 2016 · mBio
  72. The Impact of HER2/neuExpression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    Linda C. Benavides, Jeremy D. Gates, Mark G. Carmichael, Ritesh S. Patel, Jarrod P. Holmes, Matthew T. Hueman, Elizabeth Ann Mittendorf, Dianna Craig, Alexander Stojadinovic, Sathibalan Ponniah et al. · 2009 · Clinical Cancer Research
  73. Comparison of cell lines for stable production of fucose‐negative antibodies with enhanced ADCC
    Yutaka Kanda, Naoko Yamane‐Ohnuki, Naoto Sakai, Kazuya Yamano, Ryosuke Nakano, Miho Inoue, Hirofumi Misaka, Shigeru Iida, Masako Wakitani, Yoshinobu Konno et al. · 2006 · Biotechnology and Bioengineering
  74. Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
    Dariusz Pytel, Tomasz Śliwiński, Tomasz Popławski, Deborah Ferriola, Ireneusz Majsterek · 2009 · Anti-Cancer Agents in Medicinal Chemistry
  75. IgE-Antibody-Dependent Immunotherapy of Solid Tumors: Cytotoxic and Phagocytic Mechanisms of Eradication of Ovarian Cancer Cells
    Sophia N. Karagiannis, Marguerite G. Bracher, James Hunt, Natalie McCloskey, Rebecca L. Beavil, Andrew J. Beavil, David J. Fear, Richard G. Thompson, Nicholas East, Frances Burke et al. · 2007 · The Journal of Immunology
  76. Contrasting Roles of IL-2 and IL-15 in the Life and Death of Lymphocytes
    Thomas A. Waldmann, Sigrid P. Dubois, Yutaka Tagaya · 2001 · Immunity
  77. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement‐dependent anti‐tumor activity of trastuzumab and pertuzumab
    Srinivas Mamidi, Marc Cinci, Max Hasmann, Volker Fehring, Michael Kirschfink · 2013 · Molecular Oncology
  78. Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer
    Toru Mukohara · 2010 · Cancer Science
  79. Selection and Characterization of Her2 Binding-designed Ankyrin Repeat Proteins
    Christian Zahnd, Frédéric Pecorari, Nadine Straumann, Emanuel Wyler, Andreas Plückthun · 2006 · Journal of Biological Chemistry
  80. Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker
    Ezogelin Oflazoglu, Ivan J. Stone, Kristine A. Gordon, Christopher G. Wood, Elizabeth A. Repasky, Iqbal S. Grewal, Che‐Leung Law, Hans Peter Gerber · 2008 · Clinical Cancer Research
  81. Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients
    Katrin S. Reiners, Jörg Keßler, Maike Sauer, Achim Rothe, Hinrich Peter Hansen, Uwe Reusch, Christian Hucke, Ulrike Koehl, Horst Dürkop, Andreas Engert et al. · 2013 · Molecular Therapy
  82. Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31
    Katherine L. Pogue–Geile, Chungyeul Kim, Jong‐Hyeon Jeong, Noriko Tanaka, Hanna Bandos, Patrick G. Gavin, Debora Fumagalli, Lynn C. Goldstein, Nour Sneige, Eike Burandt et al. · 2013 · JNCI Journal of the National Cancer Institute
  83. Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer
    Patrick G. Gavin, Nan Song, S. Rim Kim, Corey Lipchik, Nicole L. Johnson, Hanna Bandos, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas et al. · 2016 · JAMA Oncology
  84. Diversification of IgG effector functions
    Stylianos Bournazos, Jeffrey V. Ravetch · 2017 · International Immunology
  85. Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions
    Lironne Wein, Peter Stephen Savas, Stephen James Luen, Balaji Virassamy, Roberto Salgado, Sherene Loi · 2017 · Frontiers in Oncology
  86. NK Cell-Based Immunotherapy in Cancer Metastasis
    Seila Lorenzo‐Herrero, Alejandro López‐Soto, Christian Sordo‐Bahamonde, Ana Pilar González, Massimo Vitale, Segundo R. Gonzalez · 2018 · Cancers
  87. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial
    Eugene Shenderov, Angelo Michael De Marzo, Tamara Levin Lotan, Hao Wang, Sin Chan, Su Jin Lim, Hongkai Ji, Mohamad Ezzeddine Allaf, Carolyn G. Chapman, Paul A. Moore et al. · 2023 · Nature Medicine
  88. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma
    Tarun Kewalramani, Stephen D. Nimer, Andrew David Zelenetz, S Malhotra, Jing Qin, Joachim Yahalom, Craig H. Moskowitz · 2003 · Bone Marrow Transplantation
  89. Activity of human monocytes in IgE antibody‐dependent surveillance and killing of ovarian tumor cells
    Sophia N. Karagiannis, Qin Wang, Nick East, Frances Burke, Stephane Riffard, Marguerite G. Bracher, Richard G. Thompson, Stephen R. Durham, Lawrence B. Schwartz, Frances R. Balkwill et al. · 2003 · European Journal of Immunology
  90. Ex Vivo-activated Human Macrophages Kill Chronic Lymphocytic Leukemia Cells in the Presence of Rituximab: Mechanism of Antibody-dependent Cellular Cytotoxicity and Impact of Human Serum
    Marie-Laure Lefebvre, Stefan W. Krause, Margarita Salcedo, Alessandra Nardin · 2006 · Journal of Immunotherapy
  91. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
    Josée Golay, Massimiliano Manganini, Valeria Facchinetti, Rosanna Gramigna, Raewyn C. Broady, Gianmaria Borleri, Alessandro Rambaldi, Martino Introna · 2003 · PubMed
  92. Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function
    Katharine D. Grugan, Francis L. McCabe, Michelle Kinder, Allison R. Greenplate, Benjamin C. Harman, Jason E. Ekert, Nico van Rooijen, G Mark Anderson, Jeffrey A. Nemeth, William R. Strohl et al. · 2012 · The Journal of Immunology
  93. Trastuzumab
    Karly P. Garnock-Jones, Gillian M. Keating, Lesley J. Scott · 2010 · Drugs
  94. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells
    Katri Köninki, Márk Barok, Minna Tanner, Synnöve M. Staff, Jukka Pitkänen, Päivikki Hemmilä, Joanna M. Ilvesaro, Jorma J Isola · 2010 · Cancer Letters
  95. Phenotypic Variation in IgG Receptors by Nonclassical FCGR2C Alleles
    Joris van der Heijden, Willemijn B. Breunis, Judy Geissler, Martin de Boer, Timo K. van den Berg, Taco Willem Kuijpers · 2011 · The Journal of Immunology
  96. Glycosylation of therapeutic proteins in different production systems
    Rolf G. Werner, Kristina Kopp, Michael Schlueter · 2007 · Acta Paediatrica
  97. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
    Alessandro Davide Santin, Michael W. Sill, Donald Scott McMeekin, Mario M. Leitão, Jubilee Brown, Gregory P. Sutton, Linda Van Le, Patricia C. Griffin, Cecelia H. Boardman · 2011 · Gynecologic Oncology
  98. A Phase I Study of Interleukin 12 with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressing Malignancies
    Robin Parihar, Padma C. Nadella, Adrian Lewis, Rhonda R. Jensen, Carrie De Hoff, Julie E. Dierksheide, Anne M. VanBuskirk, CYNTHIA M.J. MAGRO, Donn C. Young, Charles L. Shapiro et al. · 2004 · Clinical Cancer Research
  99. Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo
    Fubin Li, Jeffrey V. Ravetch · 2013 · Proceedings of the National Academy of Sciences
  100. Biology and clinical impact of human natural killer cells
    Sherif Shafik Farag, Jeffrey Bryan VanDeusen, Todd A. Fehniger, Michael A. Caligiuri · 2003 · International Journal of Hematology